Oleg A. Malievskiy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Oleg A. Malievskiy has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Olga B. Bezlepkina
Endocrinology Research Centre
10 shared publications - Valentina Aleksandrovna Peterkova
Endocrinology Research Centre
9 shared publications - Elena Efimovna Petryaykina
Pirogov Russian National Research Medical University
8 shared publications - Ramsiya I. Malievskaya
Bashkir State Medical University
8 shared publications - Alexey Vasil'EVich Kiyaev
Ural State Medical University; Regional Children’s Clinical Hospital
7 shared publications - Irina B. Коstrova
N.M. Kuraev Children’s Republican Clinical Hospital
7 shared publications
Latest Publications
- Open Access
- 29 June 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Open-Label 9-Year Follow-Up Extension Phase 2 Study of Once-Weekly Somatrogon in Children With Growth Hormone Deficiency
Context: : Growth hormone deficiency (GHD) can lead to significant growth and developmental issues, necessitating long-term treatment. Once-weekly somatrogon is a long-acting recombinant human growth hormone analogue, approved for treatment of children with GHD. Objective: : Assess the long-term safety and efficacy of somatrogon in children with GHD. Design: : Open-label extension (OLE) study following an initial 12-month open-label phase 2 study. Setting: : Conducted at 14 centers across Hungary, Bulgaria, Belarus, Ukraine, Russia, Greece, and the US. Patients or Other Participants: : Fifty-three children with GHD (67.9% male, mean age 6.0±2.1 years) completed the phase 2 study and 48 entered the OLE. Intervention(s): : Participants received once-weekly somatrogon for up to 9 years. Main Outcome Measure(s): : Safety endpoints included adverse events (AEs), antidrug antibodies (ADAs), local site injection reactions, and insulin-like growth factor-I SDS. Efficacy endpoints included annual height velocity (HV), change in height SDS, and annual bone maturation. Results: Treatment-emergent AEs (TEAEs) incidence was 52.1% at OLE year (Y) 1, decreasing to 23.8% by Y9. Serious AEs were rare with only isolated cases reported. ADA positivity was observed, but no neutralizing antibodies were found. No correlation between ADA presence and TEAE incidence or severity was noted, nor was there a difference in growth based on ADA presence. Mean annualized HV remained > 5 cm/year, and height SDS improved from -4.0 at baseline to -0.2 by Y8. No changes in the ratio of bone age/chronological age were observed. Conclusions: Once-weekly somatrogon is a well-tolerated and a viable long-term treatment for GHD in children. More real-world data are needed. Clinicaltrials.gov: NCT01592500.
- 29 June 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Open AccessOpen-Label 9-Year Follow-Up Extension Phase 2 Study of Once-Weekly Somatrogon in Children With Growth Hormone Deficiency
Context: : Growth hormone deficiency (GHD) can lead to significant growth and developmental issues, necessitating long-term treatment. Once-weekly somatrogon is a long-acting recombinant human growth hormone analogue, approved for treatment of children with GHD. Objective: : Assess the long-term safety and efficacy of somatrogon in children with GHD. Design: : Open-label extension (OLE) study following an initial 12-month open-label phase 2 study. Setting: : Conducted at 14 centers across Hungary, Bulgaria, Belarus, Ukraine, Russia, Greece, and the US. Patients or Other Participants: : Fifty-three children with GHD (67.9% male, mean age 6.0±2.1 years) completed the phase 2 study and 48 entered the OLE. Intervention(s): : Participants received once-weekly somatrogon for up to 9 years. Main Outcome Measure(s): : Safety endpoints included adverse events (AEs), antidrug antibodies (ADAs), local site injection reactions, and insulin-like growth factor-I SDS. Efficacy endpoints included annual height velocity (HV), change in height SDS, and annual bone maturation. Results: Treatment-emergent AEs (TEAEs) incidence was 52.1% at OLE year (Y) 1, decreasing to 23.8% by Y9. Serious AEs were rare with only isolated cases reported. ADA positivity was observed, but no neutralizing antibodies were found. No correlation between ADA presence and TEAE incidence or severity was noted, nor was there a difference in growth based on ADA presence. Mean annualized HV remained > 5 cm/year, and height SDS improved from -4.0 at baseline to -0.2 by Y8. No changes in the ratio of bone age/chronological age were observed. Conclusions: Once-weekly somatrogon is a well-tolerated and a viable long-term treatment for GHD in children. More real-world data are needed. Clinicaltrials.gov: NCT01592500.
- Open Access
- 9 June 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (5) , 366-373
Gut microbiota modulation for enhanced efficacy and reduced toxicity of chemotherapy in pediatric acute leukemias: a review
Background. Acute leukemias (AL) represent the most prevalent oncological pathology in the pediatric population. Despite the progress achieved in treatment, primarily through chemotherapy (CT) and hematopoietic stem cell transplantation, the management of this disease is associated with various complications, such as mucositis, febrile neutropenia, systemic infections, and graft-versus-host disease (GVHD). The gut microbiota (GM) plays a crucial role in modulating both the efficacy of CT and the development of its toxicity. CT-induced dysbiosis is associated with worsened treatment outcomes, underscoring the relevance of exploring strategies for its correction. Aim. To systematize current data on the role of GM in the pathogenesis of complications and the efficacy of AL therapy in children, and to analyze promising strategies for its targeted modulation aimed at improving treatment outcomes. Materials and methods. A systematic literature review was conducted in accordance with the PRISMA guidelines. The search for publications was performed in the PubMed/MEDLINE, Google Scholar, and eLIBRARY databases for the period from 2014 to 2025. Out of 5628 identified publications, after excluding duplicates and applying inclusion/exclusion criteria, 63 relevant sources were included in the analysis. Results. It was demonstrated that CT-induced dysbiosis leads to reduced alpha-diversity, characterized by a decreased abundance of commensal genera (e.g., Faecalibacterium, Lachnospiraceae) and dominance of opportunistic pathogens (e.g., Enterobacteriaceae). These alterations contribute to the development of severe mucositis, febrile neutropenia, systemic infections, and GVHD. The GM also influences the metabolism of cytostatic drugs (e.g., gemcitabine inactivation), intestinal barrier integrity (via the production of short-chain fatty acids), and the systemic immune response. Promising methods for dysbiosis correction include fecal microbiota transplantation, which has shown efficacy in steroid-refractory acute GVHD, as well as the use of probiotics, prebiotics, personalized high-fiber diets, synthetic microbial consortia, and live biotherapeutic products. Conclusion. The integration of GM modulation strategies into standard AL treatment protocols for children represents a promising approach to enhance the efficacy of CT. However, further randomized controlled trials are required to validate and standardize these strategies, focusing on the assessment of their long-term safety and efficacy.
- 9 June 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (5) , 366-373
Open AccessGut microbiota modulation for enhanced efficacy and reduced toxicity of chemotherapy in pediatric acute leukemias: a review
Background. Acute leukemias (AL) represent the most prevalent oncological pathology in the pediatric population. Despite the progress achieved in treatment, primarily through chemotherapy (CT) and hematopoietic stem cell transplantation, the management of this disease is associated with various complications, such as mucositis, febrile neutropenia, systemic infections, and graft-versus-host disease (GVHD). The gut microbiota (GM) plays a crucial role in modulating both the efficacy of CT and the development of its toxicity. CT-induced dysbiosis is associated with worsened treatment outcomes, underscoring the relevance of exploring strategies for its correction. Aim. To systematize current data on the role of GM in the pathogenesis of complications and the efficacy of AL therapy in children, and to analyze promising strategies for its targeted modulation aimed at improving treatment outcomes. Materials and methods. A systematic literature review was conducted in accordance with the PRISMA guidelines. The search for publications was performed in the PubMed/MEDLINE, Google Scholar, and eLIBRARY databases for the period from 2014 to 2025. Out of 5628 identified publications, after excluding duplicates and applying inclusion/exclusion criteria, 63 relevant sources were included in the analysis. Results. It was demonstrated that CT-induced dysbiosis leads to reduced alpha-diversity, characterized by a decreased abundance of commensal genera (e.g., Faecalibacterium, Lachnospiraceae) and dominance of opportunistic pathogens (e.g., Enterobacteriaceae). These alterations contribute to the development of severe mucositis, febrile neutropenia, systemic infections, and GVHD. The GM also influences the metabolism of cytostatic drugs (e.g., gemcitabine inactivation), intestinal barrier integrity (via the production of short-chain fatty acids), and the systemic immune response. Promising methods for dysbiosis correction include fecal microbiota transplantation, which has shown efficacy in steroid-refractory acute GVHD, as well as the use of probiotics, prebiotics, personalized high-fiber diets, synthetic microbial consortia, and live biotherapeutic products. Conclusion. The integration of GM modulation strategies into standard AL treatment protocols for children represents a promising approach to enhance the efficacy of CT. However, further randomized controlled trials are required to validate and standardize these strategies, focusing on the assessment of their long-term safety and efficacy.
- 4 May 2026
- Published by ECO-Vector LLC (Publications) in Russian Journal of Oncology
The modern perspective on the role of microbiota in childhood chemotherapy
The gut microbiota (GM) plays a pivotal role in modulating both the efficacy and toxicity of chemotherapy (CT) in pediatric oncology patients, underscoring the relevance of this review. The authors analyzed and systematized current literature data on the role of GM in treatment tolerance and efficacy, particularly in acute leukemia (AL). The existence of a complex bidirectional relationship between CT and GM is demonstrated. CT induces dysbiotic shifts in the GM, characterized by reduced alpha-diversity, depletion of commensal genera, and an increase in the abundance of opportunistic pathogens, which serves as a predictor of complications such as mucositis, febrile neutropenia, and sepsis. Conversely, GM exerts influence on CT through direct effects on the metabolism of cytostatic agents and systemic immunomodulation. A key mechanism of GM's influence is the production of short-chain fatty acids (SCFAs), particularly butyrate, which enhances the function of cytotoxic T-lymphocytes, induces apoptosis in tumor cells, and reinforces intestinal barrier integrity. Promising strategies for correcting dysbiosis include probiotics, prebiotics, and fecal microbiota transplantation (FMT), the latter demonstrating high efficacy in steroid-refractory graft-versus-host disease (GVHD). The integration of microbiome-based biomarkers into predictive models and the application of multi-omics technologies pave the way for the development of personalized treatment approaches. In conclusion, GM is a significant factor determining the outcomes of CT in children, and strategies aimed at its modulation hold considerable potential for improving patient survival and quality of life, although further validation through randomized controlled trials is warranted.
- 4 May 2026
- Published by ECO-Vector LLC (Publications) in Russian Journal of Oncology
The modern perspective on the role of microbiota in childhood chemotherapy
The gut microbiota (GM) plays a pivotal role in modulating both the efficacy and toxicity of chemotherapy (CT) in pediatric oncology patients, underscoring the relevance of this review. The authors analyzed and systematized current literature data on the role of GM in treatment tolerance and efficacy, particularly in acute leukemia (AL). The existence of a complex bidirectional relationship between CT and GM is demonstrated. CT induces dysbiotic shifts in the GM, characterized by reduced alpha-diversity, depletion of commensal genera, and an increase in the abundance of opportunistic pathogens, which serves as a predictor of complications such as mucositis, febrile neutropenia, and sepsis. Conversely, GM exerts influence on CT through direct effects on the metabolism of cytostatic agents and systemic immunomodulation. A key mechanism of GM's influence is the production of short-chain fatty acids (SCFAs), particularly butyrate, which enhances the function of cytotoxic T-lymphocytes, induces apoptosis in tumor cells, and reinforces intestinal barrier integrity. Promising strategies for correcting dysbiosis include probiotics, prebiotics, and fecal microbiota transplantation (FMT), the latter demonstrating high efficacy in steroid-refractory graft-versus-host disease (GVHD). The integration of microbiome-based biomarkers into predictive models and the application of multi-omics technologies pave the way for the development of personalized treatment approaches. In conclusion, GM is a significant factor determining the outcomes of CT in children, and strategies aimed at its modulation hold considerable potential for improving patient survival and quality of life, although further validation through randomized controlled trials is warranted.
- Open Access
- 18 January 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (6) , 97-101
Hypogonadotropic hypogonadism due to pathogenic variants in the POLR3B gene
Congenital hypogonadotropic hypogonadism (СНH) is a group of diseases caused by impaired synthesis or secretion of gonadotropin-releasing hormone (GnRH) and gonadotropin hormones. At present, more than twenty genes involved in the development of СНН have been described. In the structure of HGH, the most common forms of the disease are caused by pathogenic variants in genes involved in the ontogenesis, migration and survival of GnRH neurons, whereas pathology of genes involved in the action/transmission of GnRH signals in normally developed GnRH neurons is less common. This article describes a rare variant of СНН as a result of pathogenic variants in the POLR3B gene, occurring in 1.1% of cases of СНН, which is a component of hypomyelinating leukodystrophy 4H and includes hypomyelination, CHН, hypodontia. Identification of the genetic nature of the disease in this patient made it possible not only to establish the cause of CНН, but also to diagnose comorbid conditions.
- 18 January 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (6) , 97-101
Open AccessHypogonadotropic hypogonadism due to pathogenic variants in the POLR3B gene
Congenital hypogonadotropic hypogonadism (СНH) is a group of diseases caused by impaired synthesis or secretion of gonadotropin-releasing hormone (GnRH) and gonadotropin hormones. At present, more than twenty genes involved in the development of СНН have been described. In the structure of HGH, the most common forms of the disease are caused by pathogenic variants in genes involved in the ontogenesis, migration and survival of GnRH neurons, whereas pathology of genes involved in the action/transmission of GnRH signals in normally developed GnRH neurons is less common. This article describes a rare variant of СНН as a result of pathogenic variants in the POLR3B gene, occurring in 1.1% of cases of СНН, which is a component of hypomyelinating leukodystrophy 4H and includes hypomyelination, CHН, hypodontia. Identification of the genetic nature of the disease in this patient made it possible not only to establish the cause of CНН, but also to diagnose comorbid conditions.
- Open Access
- 1 January 2026
- Published by NP Rusmedical Group in Doctor.Ru
A Multifactorial Model for Predicting Insulin Resistance in Patients with Type 1 Diabetes Mellitus
Aim. To develop a multivariate model for predicting insulin resistance in male and female patients with type 1 diabetes mellitus (T1DM). Design. Cross-sectional study. Materials and methods. The study included 317 adult patients (156 men and 161 women). The median age was 29 years; the median duration of T1DM was 13 years; the median body mass index (BMI) was 22.5 kg/m2; and the median glycated haemoglobin (HbA1c) was 9.4%. Physical inactivity was observed in 32 (10.1%) subjects; arterial hypertension was reported in 68 (21.5%) patients; and 86 (27.1%) patients were overweight. Anamnestic, anthropometric, and laboratory methods were used. Insulin resistance was diagnosed at an estimated insulin sensitivity of ≤ 5.02 mg/kg/min in men and ≤ 5.64 mg/kg/min in women, determined using the equation of D. Dabelea et al. (2011). To assess the association between qualitative attributes, the odds ratio with a 95% confidence interval was calculated. The null hypothesis was rejected at p < 0.05. ROC analysis was performed to identify the threshold levels of indicators, and their sensitivity and specificity were calculated. Wald’s sequential analysis was used to develop models for predicting insulin resistance. Results. The multivariate model for predicting insulin resistance in male patients included the following risk factors: age over 33 years; T1DM duration of over 19 years; BMI of 30 kg/m2 and above; waist circumference of over 84.5 cm; physical inactivity; total cholesterol > 4.87 mmol/L; low-density lipoprotein cholesterol > 3.22 mmol/L; triglycerides > 1.29 mmol/L; HbA1c > 9.4%; and the PIK3R1 gene rs3730089 AC genotype. In women, the model included: age over 37 years; T1DM duration of over 20 years; BMI of 30 kg/m2 and above; waist circumference of over 78 cm; physical inactivity; a family history of type 2 diabetes mellitus and overweight; total cholesterol > 4.80 mmol/L; low-density lipoprotein cholesterol > 2.83 mmol/L; triglycerides > 1.22 mmol/L; HbA1c > 9.9%; and the PIK3R1 gene rs3730089 AC genotype. Conclusion. This multivariate model allows for the prediction of insulin resistance in male and female patients with T1DM using readily available clinical and laboratory indicators. Keywords: type 1 diabetes mellitus, insulin resistance, risk factors
- 1 January 2026
- Published by NP Rusmedical Group in Doctor.Ru
Open AccessA Multifactorial Model for Predicting Insulin Resistance in Patients with Type 1 Diabetes Mellitus
Aim. To develop a multivariate model for predicting insulin resistance in male and female patients with type 1 diabetes mellitus (T1DM). Design. Cross-sectional study. Materials and methods. The study included 317 adult patients (156 men and 161 women). The median age was 29 years; the median duration of T1DM was 13 years; the median body mass index (BMI) was 22.5 kg/m2; and the median glycated haemoglobin (HbA1c) was 9.4%. Physical inactivity was observed in 32 (10.1%) subjects; arterial hypertension was reported in 68 (21.5%) patients; and 86 (27.1%) patients were overweight. Anamnestic, anthropometric, and laboratory methods were used. Insulin resistance was diagnosed at an estimated insulin sensitivity of ≤ 5.02 mg/kg/min in men and ≤ 5.64 mg/kg/min in women, determined using the equation of D. Dabelea et al. (2011). To assess the association between qualitative attributes, the odds ratio with a 95% confidence interval was calculated. The null hypothesis was rejected at p < 0.05. ROC analysis was performed to identify the threshold levels of indicators, and their sensitivity and specificity were calculated. Wald’s sequential analysis was used to develop models for predicting insulin resistance. Results. The multivariate model for predicting insulin resistance in male patients included the following risk factors: age over 33 years; T1DM duration of over 19 years; BMI of 30 kg/m2 and above; waist circumference of over 84.5 cm; physical inactivity; total cholesterol > 4.87 mmol/L; low-density lipoprotein cholesterol > 3.22 mmol/L; triglycerides > 1.29 mmol/L; HbA1c > 9.4%; and the PIK3R1 gene rs3730089 AC genotype. In women, the model included: age over 37 years; T1DM duration of over 20 years; BMI of 30 kg/m2 and above; waist circumference of over 78 cm; physical inactivity; a family history of type 2 diabetes mellitus and overweight; total cholesterol > 4.80 mmol/L; low-density lipoprotein cholesterol > 2.83 mmol/L; triglycerides > 1.22 mmol/L; HbA1c > 9.9%; and the PIK3R1 gene rs3730089 AC genotype. Conclusion. This multivariate model allows for the prediction of insulin resistance in male and female patients with T1DM using readily available clinical and laboratory indicators. Keywords: type 1 diabetes mellitus, insulin resistance, risk factors
- 1 January 2026
- Published by Dynasty Publishing House in Voprosy praktičeskoj pediatrii
- Vol. 21 (1)
Saccharomyces boulardii CNCM I-745: a renaissance in the treatment of small intestinal bacterial overgrowth in children?
The increasing prevalence of small intestinal bacterial overgrowth (SIBO) in the pediatric population necessitates the search for alternative therapeutic methods that can reduce the frequency of antibacterial drug use. One such alternative may be the use of the drug Enterol®, containing the non-bacterial probiotic strain Saccharomyces boulardii CNCM I-745. Despite its proven efficacy in adults, data on its use in children with SIBO are limited, which determined the objective of this study. Objective. To study the comparative efficacy of monotherapy for SIBO using the non-bacterial probiotic strain S. boulardii CNCM I-745 versus metronidazole in children. Patients and methods. The prospective study included 88 children (12–17 years old) with a verified diagnosis of SIBO. Patients were randomized into 2 groups: the main group (n = 43) received S. boulardii CNCM I-745 (the drug Enterol®, Biocodex, France) (1000 mg/day), the comparison group (n = 45) received metronidazole (20 mg/kg/day) for 14 days. The rate of small intestinal decontamination (according to hydrogen breath test data) and the dynamics of symptoms on a binary scale (0–1 points) were assessed 1 month after treatment. Results. The decontamination rate in the group of patients taking Enterol® was almost 2 times higher, amounting to 83.7% (36/43) versus 42.2% (19/45) in the comparison group (p = 0.0001). Both groups showed a decrease in the total symptom index, but the regression was more pronounced in the main group (from 6 to 2 points). After therapy, nausea, vomiting, belching, dyspepsia, and diarrhea were completely resolved in both groups. Complaints of abdominal pain, bloating, and feeling of fullness persisted significantly less frequently in the main group (16.3%, 9.3%, and 4.7%, respectively) than in the comparison group (53.3%, 42.2%, and 31.1%, respectively; p < 0.05). Conclusion. The use of the drug Enterol®, containing the non-bacterial probiotic strain S. boulardii CNCM I-745, in children with SIBO demonstrates higher decontamination and clinical efficacy compared to metronidazole. The obtained data allow this probiotic to be considered as a means of correcting dysbiosis in SIBO. Key words: small intestinal bacterial overgrowth, Saccharomyces boulardii CNCM I-745, metronidazole, children, hydrogen breath test
- 1 January 2026
- Published by Dynasty Publishing House in Voprosy praktičeskoj pediatrii
- Vol. 21 (1)
Saccharomyces boulardii CNCM I-745: a renaissance in the treatment of small intestinal bacterial overgrowth in children?
The increasing prevalence of small intestinal bacterial overgrowth (SIBO) in the pediatric population necessitates the search for alternative therapeutic methods that can reduce the frequency of antibacterial drug use. One such alternative may be the use of the drug Enterol®, containing the non-bacterial probiotic strain Saccharomyces boulardii CNCM I-745. Despite its proven efficacy in adults, data on its use in children with SIBO are limited, which determined the objective of this study. Objective. To study the comparative efficacy of monotherapy for SIBO using the non-bacterial probiotic strain S. boulardii CNCM I-745 versus metronidazole in children. Patients and methods. The prospective study included 88 children (12–17 years old) with a verified diagnosis of SIBO. Patients were randomized into 2 groups: the main group (n = 43) received S. boulardii CNCM I-745 (the drug Enterol®, Biocodex, France) (1000 mg/day), the comparison group (n = 45) received metronidazole (20 mg/kg/day) for 14 days. The rate of small intestinal decontamination (according to hydrogen breath test data) and the dynamics of symptoms on a binary scale (0–1 points) were assessed 1 month after treatment. Results. The decontamination rate in the group of patients taking Enterol® was almost 2 times higher, amounting to 83.7% (36/43) versus 42.2% (19/45) in the comparison group (p = 0.0001). Both groups showed a decrease in the total symptom index, but the regression was more pronounced in the main group (from 6 to 2 points). After therapy, nausea, vomiting, belching, dyspepsia, and diarrhea were completely resolved in both groups. Complaints of abdominal pain, bloating, and feeling of fullness persisted significantly less frequently in the main group (16.3%, 9.3%, and 4.7%, respectively) than in the comparison group (53.3%, 42.2%, and 31.1%, respectively; p < 0.05). Conclusion. The use of the drug Enterol®, containing the non-bacterial probiotic strain S. boulardii CNCM I-745, in children with SIBO demonstrates higher decontamination and clinical efficacy compared to metronidazole. The obtained data allow this probiotic to be considered as a means of correcting dysbiosis in SIBO. Key words: small intestinal bacterial overgrowth, Saccharomyces boulardii CNCM I-745, metronidazole, children, hydrogen breath test
- 5 August 2025
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 106 (4) , 517-525
Features of type 1 diabetes mellitus in adults depending on the presence of insulin resistance
BACKGROUND: Insulin resistance contributes to the clinical course of type 1 diabetes mellitus and increases complication risk in adults. AIM: This study aimed to assess the clinical characteristics of type 1 diabetes mellitus and prevalence of its complications among men and women with and without insulin resistance. METHODS: Overall, 317 adults with type 1 diabetes mellitus were examined. The participants were divided into two groups: group 1, 81 patients with insulin resistance; and group 2, 236 patients without insulin resistance. Lipid metabolism parameters and prevalence of macrovascular and microvascular complications were assessed in each group. Anthropometric and laboratory studies included serum creatinine levels with subsequent estimation of glomerular filtration rate, total cholesterol, high- and low-density lipoproteins, triglycerides, and urinary albumin excretion in a random sample. Instrumental examinations involved electroneuromyography, duplex ultrasound scanning of the lower-limb arteries, and fundus examination. Insulin resistance was defined as an estimated insulin sensitivity ≤5.02 in men and ≤5.64 in women. Quantitative data with non-normal distribution were presented as median and 95% confidence interval. For normally distributed variables, the mean and standard deviation were calculated. Categorical data were presented as absolute and relative frequencies. Differences in quantitative parameters were assessed using the Mann–Whitney U test and differences in categorical indicators using the χ2 test. P 0.05 indicated significant differences. RESULTS: Insulin resistance prevalence among all patients was 25.6%. Compared to patients without insulin resistance, men and women with insulin resistance more frequently had overweight or obesity (men: 57.1% vs 12.3%, p 0.001; women: 56.4% vs 21.3%, p 0.001), higher total cholesterol levels (men: 5.3 vs 4.6 mmol/L, p 0.001; women: 5.6 vs 4.7 mmol/L, p 0.001), and increased low-density lipoprotein levels (men: 3.4 vs 2.8 mmol/L, p 0.001; women: 3.2 vs 2.7 mmol/L, p 0.001). Men with insulin resistance were more likely to experience hypertension (47.6% vs 14.9%, p 0.001), atherosclerosis (38.1% vs 14.9%, p = 0.004), diabetic nephropathy (54.8% vs 18.4%, p 0.001), and retinopathy (81.0% vs 56.1%, p = 0.008). Hypertension (46.1% vs 13.9%, p 0.001) and atherosclerosis (30.8% vs 11.5%, p = 0.010) were more prevalent in women with insulin resistance. CONCLUSION: The clinical course of type 1 diabetes mellitus in patients with insulin resistance is characterized by increased cholesterol and low-density lipoprotein levels, higher prevalence of overweight or obesity, and greater incidence of macrovascular complications compared to patients without insulin resistance.
- 5 August 2025
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 106 (4) , 517-525
Features of type 1 diabetes mellitus in adults depending on the presence of insulin resistance
BACKGROUND: Insulin resistance contributes to the clinical course of type 1 diabetes mellitus and increases complication risk in adults. AIM: This study aimed to assess the clinical characteristics of type 1 diabetes mellitus and prevalence of its complications among men and women with and without insulin resistance. METHODS: Overall, 317 adults with type 1 diabetes mellitus were examined. The participants were divided into two groups: group 1, 81 patients with insulin resistance; and group 2, 236 patients without insulin resistance. Lipid metabolism parameters and prevalence of macrovascular and microvascular complications were assessed in each group. Anthropometric and laboratory studies included serum creatinine levels with subsequent estimation of glomerular filtration rate, total cholesterol, high- and low-density lipoproteins, triglycerides, and urinary albumin excretion in a random sample. Instrumental examinations involved electroneuromyography, duplex ultrasound scanning of the lower-limb arteries, and fundus examination. Insulin resistance was defined as an estimated insulin sensitivity ≤5.02 in men and ≤5.64 in women. Quantitative data with non-normal distribution were presented as median and 95% confidence interval. For normally distributed variables, the mean and standard deviation were calculated. Categorical data were presented as absolute and relative frequencies. Differences in quantitative parameters were assessed using the Mann–Whitney U test and differences in categorical indicators using the χ2 test. P 0.05 indicated significant differences. RESULTS: Insulin resistance prevalence among all patients was 25.6%. Compared to patients without insulin resistance, men and women with insulin resistance more frequently had overweight or obesity (men: 57.1% vs 12.3%, p 0.001; women: 56.4% vs 21.3%, p 0.001), higher total cholesterol levels (men: 5.3 vs 4.6 mmol/L, p 0.001; women: 5.6 vs 4.7 mmol/L, p 0.001), and increased low-density lipoprotein levels (men: 3.4 vs 2.8 mmol/L, p 0.001; women: 3.2 vs 2.7 mmol/L, p 0.001). Men with insulin resistance were more likely to experience hypertension (47.6% vs 14.9%, p 0.001), atherosclerosis (38.1% vs 14.9%, p = 0.004), diabetic nephropathy (54.8% vs 18.4%, p 0.001), and retinopathy (81.0% vs 56.1%, p = 0.008). Hypertension (46.1% vs 13.9%, p 0.001) and atherosclerosis (30.8% vs 11.5%, p = 0.010) were more prevalent in women with insulin resistance. CONCLUSION: The clinical course of type 1 diabetes mellitus in patients with insulin resistance is characterized by increased cholesterol and low-density lipoprotein levels, higher prevalence of overweight or obesity, and greater incidence of macrovascular complications compared to patients without insulin resistance.
- Open Access
- 24 July 2025
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 28 (3) , 214-222
Prevalence of insulin resistance based on the estimated rate of glucose utilization among adult patients with type 1 diabetes and its role in predicting diabetic complications
BACKGROUND: The significance of determining insulin resistance (IR) in people with type 1 diabetes mellitus (T1DM) is determined by the acceleration of the transition from the first stage of development of T1DM to the second and third, and is also a risk factor for the development of chronic complications of diabetes. The lack of a unified criterion for determining metabolically significant insulin resistance in patients with T1DM determines the need to study this problem.AIM: To study the incidence of insulin resistance in individuals with T1DM over 18 years of age and disease duration of more than 1 year based on the estimated rate of glucose utilization and to determine the association between the eGDR value MATERIALS AND METHODS: 201 patients with T1DM over 18 years of age and T1DM duration of more than 1 year were examined. Among them, 95 (47%) were men, 106 (53%) were women. Median age was 30.0 [28.1; 33.0] years, median duration of T1DM — 13 [12; 15] years. The estimated rate of glucose utilization was estimated using the equation of Williams K. et al. (2000). Patients with an eGDR value RESULTS: The value of eGDR CONCLUSION: The fairly high prevalence of IR among patients with type 1 diabetes, the risk of developing diabetic nephropathy and atherosclerosis of the arteries of the lower extremities in these individuals, justifies the need to identify this condition in clinical practice in order to improve the course of type 1 diabetes.
- 24 July 2025
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 28 (3) , 214-222
Open AccessPrevalence of insulin resistance based on the estimated rate of glucose utilization among adult patients with type 1 diabetes and its role in predicting diabetic complications
BACKGROUND: The significance of determining insulin resistance (IR) in people with type 1 diabetes mellitus (T1DM) is determined by the acceleration of the transition from the first stage of development of T1DM to the second and third, and is also a risk factor for the development of chronic complications of diabetes. The lack of a unified criterion for determining metabolically significant insulin resistance in patients with T1DM determines the need to study this problem.AIM: To study the incidence of insulin resistance in individuals with T1DM over 18 years of age and disease duration of more than 1 year based on the estimated rate of glucose utilization and to determine the association between the eGDR value MATERIALS AND METHODS: 201 patients with T1DM over 18 years of age and T1DM duration of more than 1 year were examined. Among them, 95 (47%) were men, 106 (53%) were women. Median age was 30.0 [28.1; 33.0] years, median duration of T1DM — 13 [12; 15] years. The estimated rate of glucose utilization was estimated using the equation of Williams K. et al. (2000). Patients with an eGDR value RESULTS: The value of eGDR CONCLUSION: The fairly high prevalence of IR among patients with type 1 diabetes, the risk of developing diabetic nephropathy and atherosclerosis of the arteries of the lower extremities in these individuals, justifies the need to identify this condition in clinical practice in order to improve the course of type 1 diabetes.
- Open Access
- 1 January 2025
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 14 (2)
Search for genetic markers of insulin resistance in type 1 diabetes mellitus
Поиск генетических маркеров инсулинорезистентности при сахарном диабете 1 типа
- 1 January 2025
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 14 (2)
Open AccessSearch for genetic markers of insulin resistance in type 1 diabetes mellitus
Поиск генетических маркеров инсулинорезистентности при сахарном диабете 1 типа
- Open Access
- 1 January 2025
- Published by NP Rusmedical Group in Doctor.Ru
Association of the rs3730089 Nucleotide Sequence of the PIK3R1 Gene with Dyslipidemia in Type 1 Diabetes Mellitus
Aim. To analyze the association of the rs3730089 nucleotide sequence variant of the PIK3R1 gene with various metabolic disorders in patients with type 1 diabetes mellitus (T1DM). Design. A one-stage cross-sectional study. Materials and methods. 147 unrelated patients with T1DM were examined. Their height, body weight, waist and hip circumferences, and body mass index were measured. Laboratory tests included the determination of total cholesterol, high- and low-density lipoprotein cholesterol, and triglycerides. The variant of the nucleotide sequence was investigated using a polymerase chain reaction. Using the χ2 criterion, the correspondence of the frequency of genotypes to the Hardy — Weinberg equilibrium was estimated. The association of genotypes with insulin resistance was analyzed using the online SNPStats program. Association analysis is presented in codominant, dominant, recessive, overdominant, and additive models, as well as during the allele test. Results. The distribution of genotypes and alleles of the rs3730089 nucleotide sequence variant of the PIK3R1 gene in all patients corresponded to the Hardy — Weinberg equilibrium. There was a significant association of A/C and A/A genotypes in dominant models with elevated levels of low-density lipoproteins and cholesterol. In the overdominant model, the association of the A/C genotype with elevated triglyceride levels, as well as with increased waist circumference and overweight in patients with Т1DM was determined (odds ratio — 10.5, 95% confidence interval: 3.94–27.99, p < 0.0001, рFDR = 0.0001 and odds ratio — 5.70, 95% confidence interval: 2.28–14.26, p = 0.0001, рFDR = 0.0002, respectively). For all of the above indicators, allele A was risky. Associations of genotypes and alleles of the rs3730089 nucleotide sequence variant of the PIK3R1 gene with a reduced level of high-density lipoproteins have not been found. Conclusion. The nucleotide sequence rs3730089 of the PIK3R1 gene is associated with lipid metabolism disorders in patients with Т1DM. Allele A is risky. This variant of the nucleotide sequence may be associated with insulin resistance in people with T1DM. Keywords: type 1 diabetes mellitus, PIK3R1 gene, nucleotide sequence rs3730089, dyslipidemia.
- 1 January 2025
- Published by NP Rusmedical Group in Doctor.Ru
Open AccessAssociation of the rs3730089 Nucleotide Sequence of the PIK3R1 Gene with Dyslipidemia in Type 1 Diabetes Mellitus
Aim. To analyze the association of the rs3730089 nucleotide sequence variant of the PIK3R1 gene with various metabolic disorders in patients with type 1 diabetes mellitus (T1DM). Design. A one-stage cross-sectional study. Materials and methods. 147 unrelated patients with T1DM were examined. Their height, body weight, waist and hip circumferences, and body mass index were measured. Laboratory tests included the determination of total cholesterol, high- and low-density lipoprotein cholesterol, and triglycerides. The variant of the nucleotide sequence was investigated using a polymerase chain reaction. Using the χ2 criterion, the correspondence of the frequency of genotypes to the Hardy — Weinberg equilibrium was estimated. The association of genotypes with insulin resistance was analyzed using the online SNPStats program. Association analysis is presented in codominant, dominant, recessive, overdominant, and additive models, as well as during the allele test. Results. The distribution of genotypes and alleles of the rs3730089 nucleotide sequence variant of the PIK3R1 gene in all patients corresponded to the Hardy — Weinberg equilibrium. There was a significant association of A/C and A/A genotypes in dominant models with elevated levels of low-density lipoproteins and cholesterol. In the overdominant model, the association of the A/C genotype with elevated triglyceride levels, as well as with increased waist circumference and overweight in patients with Т1DM was determined (odds ratio — 10.5, 95% confidence interval: 3.94–27.99, p < 0.0001, рFDR = 0.0001 and odds ratio — 5.70, 95% confidence interval: 2.28–14.26, p = 0.0001, рFDR = 0.0002, respectively). For all of the above indicators, allele A was risky. Associations of genotypes and alleles of the rs3730089 nucleotide sequence variant of the PIK3R1 gene with a reduced level of high-density lipoproteins have not been found. Conclusion. The nucleotide sequence rs3730089 of the PIK3R1 gene is associated with lipid metabolism disorders in patients with Т1DM. Allele A is risky. This variant of the nucleotide sequence may be associated with insulin resistance in people with T1DM. Keywords: type 1 diabetes mellitus, PIK3R1 gene, nucleotide sequence rs3730089, dyslipidemia.